@article{2c75f52d22d04dc587b5fce691752a03,
title = "Clinical Efficacy and Safety of Psoriasis Treatments in Patients with Concomitant Metabolic Syndrome: A Narrative Review",
abstract = "Metabolic syndrome (MetS) is well recognized as a frequent comorbidity of psoriasis with important implications for efficacy and safety of psoriasis treatment. The presence of concomitant MetS is associated with decreased efficacy response to biologic treatment for psoriasis in observational studies. In post hoc analyses of clinical trial data, the anti–IL-23p19 antibody tildrakizumab appears to maintain efficacy in patients compared to those without MetS; no published subgroup analyses by MetS status are yet available for other biologics. However, there is some evidence that obese patients have decreased psoriasis treatment efficacy with biologics with certain mechanisms of action relative to overweight patients. This confounds interpretation of the effect of MetS due to the association between MetS and body weight. Because of the association between MetS and cardiovascular risk, treatment of psoriasis in patients with concomitant MetS requires special consideration for cardiovascular safety and attention to potential for exacerbation of MetS and related conditions, including nonalcoholic fatty liver disease. Additional studies are needed to clarify the risks for treatment failure and cardiovascular safety concerns in patients with psoriasis and concomitant MetS.",
keywords = "Biologic therapy, Metabolic syndrome, Psoriasis",
author = "Merola, {Joseph F.} and Arthur Kavanaugh and Lebwohl, {Mark G.} and Robert Gniadecki and Wu, {Jashin J.}",
note = "Funding Information: Funding for Dermatology and Therapy{\textquoteright}s Rapid Service Fee was provided by Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA. Funding Information: Funding for Dermatology and Therapy{\textquoteright}s Rapid Service Fee was provided by Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA. Medical writing and editorial assistance was provided by Hilary Durbano, PhD, of AlphaBioCom, LLC, King of Prussia, PA, USA, and funded by Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. All named authors contributed to the conception and design of this review. All authors contributed to writing the first draft and commented on previous versions of the manuscript. All authors read and approved the final manuscript. Joseph F. Merola is a consultant for AbbVie; Amgen; Biogen; Bristol Myers Squibb; Dermavant; Eli Lilly; Janssen; LEO Pharma; Novartis; Pfizer; Regeneron; Sanofi; Sun Pharmaceutical Industries, Inc.; and UCB. Arthur Kavanaugh has conducted clinical research sponsored by and/or consulted for AbbVie, Amgen, Celgene, Eli Lilly, Novartis, and Pfizer. Mark G. Lebwohl is an employee of Mount Sinai and receives research funds from AbbVie; Amgen; Arcutis; Avotres; Boehringer Ingelheim; Dermavant Sciences; Eli Lilly; Incyte; Janssen Research & Development, LLC; Ortho Dermatologics; Regeneron; and UCB, Inc.; is a consultant for Aditum Bio; Almirall; AltruBio Inc.; AnaptysBio; Arcutis; Aristea Therapeutics; Arrive Technologies; Avotres Therapeutics; BiomX; Boehringer Ingelheim; Bristol Myers Squibb; Cara Therapeutics; Castle Biosciences; Corrona; Dermavant Sciences; Dr. Reddy{\textquoteright}s Laboratories; Evelo Biosciences; Evommune, Inc.; Facilitation of International Dermatology Education; Forte Biosciences; Foundation for Research and Education in Dermatology; Helsinn Therapeutics; Hexima Ltd.; LEO Pharma; Meiji Seika Pharma; Mindera; Pfizer; Seanergy; and Verrica. Robert Gniadecki has served on advisory boards and/or received lecture honoraria from AbbVie; Amgen; Celgene; Eli Lilly; Janssen Research & Development, LLC; LEO Pharma; Mallinckrodt; Merck; and Novartis. Jashin J. Wu is or has been an investigator for AbbVie, Amgen, Eli Lilly, Janssen, Novartis; a consultant for AbbVie; Almirall; Amgen; Arcutis; Aristea Therapeutics; Bausch Health; Boehringer Ingelheim; Bristol Myers Squibb; Dermavant; Dr. Reddy's Laboratories; Eli Lilly; Galderma; Janssen; LEO Pharma; Mindera Novartis; Regeneron; Sanofi Genzyme; Solius; Sun Pharmaceutical Industries, Inc.; UCB; and Zerigo Health; and a speaker for AbbVie; Amgen; Bausch Health; Novartis; Regeneron; Sanofi Genzyme; Sun Pharmaceutical Industries, Inc.; and UCB. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
month = oct,
doi = "10.1007/s13555-022-00790-2",
language = "English",
volume = "12",
pages = "2201--2216",
journal = "Dermatology and Therapy",
issn = "2190-9172",
publisher = "Springer Verlag",
number = "10",
}